NDA 218923. Not in Drugs@FDA, which lists approved applications only; FDA's complete response letters name it.
As of Nov 16, 2026, NDA 218923 (Irinotecan liposome) is not in Drugs@FDA, which lists approved applications; FDA has published 2 complete response letters for it.
| Jul 30, 2025 | Irinotecan liposomeFacility Inspections, Clinical | Unapproved |
| Oct 10, 2024 | Irinotecan liposomeFacility Inspections, Clinical | Unapproved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters